Jan 30 (Reuters) - The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' (VRTX.O), opens new tab drug to treat acute pain, the health regulator said on Thursday, offering a ...

Shares of Medtronic (NYSE: MDT) are off to a fantastic start in 2025, already rising by 13% year to date. The medical devices giant had some weakness in recent years amid disappointing trends from ...

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...

Shares of Medtronic are benefiting from an improved earnings growth outlook. The company is capturing strong demand for its new lineup of high-tech medical devices. The stock trades at just 16 ...

Square parent Block and Shopify are trading around buy points despite market volatility around big earnings and Trump tariffs ...

BOSTON, January 12, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the ...

At the 43rd annual J.P. Morgan Healthcare Conference on Monday, Medtronic CEO Geoff Martha mixed in some breaking news with his usual pitch to investors. Just hours earlier, the Centers for ...

Vertex Pharmaceuticals is hoping to build upon its existing rare blood disease treatment portfolio, teaming up with Orna Therapeutics’ ReNAgade in efforts to develop next-gen gene therapies for ...

Get Wall Street's Hottest Chart Every Morning RBC Capital Markets says Vertex management is optimistic about the recently approved Alyftrek. They predict that most of the 6,000 patients who ...

SAN FRANCISCO—While deep-brain stimulation therapy has been available for people with Parkinson’s disease for decades, Medtronic has now received a European approval for what it describes as ...

Vertex has been running a number of trials because if there’s one thing that we can take away from the failed drug development projects of the past, it’s that there are many kinds of pain.

We're kicking off the 43rd Annual Healthcare Conference this morning, and I couldn't be more delighted to introduce Vertex's CEO, Reshma Kewalramani. She's going to come on stage to give a ...